Navigation Links
Diabetes - New Treatment Approach At John Hopkins

Diabetes, a modern disease, can be now treated by a new approach involving release of sugar by liver cells. Initial experiment were made with mice by scientists // at John Hopkins Institute of Basic Biomedical Sciences and McKusick-Nathans Institute for Genetic Medicine.

The discovery by researchers in Hopkins' Institute of Basic Biomedical Sciences and McKusick-Nathans Institute for Genetic Medicine reveals that a protein called GCN5 is critical for controlling a domino-like cascade of molecular events that lead to the release of sugar from liver cells into the bloodstream. Understanding the role of GCN5 in maintaining blood sugar levels is leading to a clearer picture of how the body uses sugar and other nutrients to make, store and spend energy.

‘Understanding the ways that energy production and use are controlled is crucial to developing new drugs and therapies,’ says the report's senior author, Pere Puigserver, Ph.D., an assistant professor of cell biology at Hopkins.

The inability to properly regulate blood sugar levels leads to conditions like obesity and diabetes. Both type 1 and type 2 diabetes cause blood sugar levels to stay too high, which can lead to complications like blindness, kidney failure and nerve damage.

‘Diabetes is a really big problem, even when patients are given insulin and stay on strict diets,’ says Carles Lerin, Ph.D., a postdoctoral fellow in cell biology at Hopkins and an author of the report. ‘In the absence of a cure for the disease, we are really trying to focus on finding better treatment because currently available methods just don't work that efficiently,’ he says.

The body keeps blood sugar – known as glucose – within a narrow range. Extra glucose floating through the bloodstream, which is common after eating a meal, is captured and kept in the liver. When blood glucose runs low, the liver releases its stores back into the bloodstream. When those reserves are tapped out, liver cells turn on genes to make more glucose to fuel the body.

The research team found that GCN5 chemically alters another protein called PGC-1alpha that normally turns on a set of genes to manufacture enzymes required for glucose release. When GCN5 is fully functional in liver cells, this cascade is turned off and glucose is not released from those cells. Removal of functional GCN5 from liver cells restores the cells' ability to release glucose.

The researchers showed that GCN5 alters its target, sabotaging it by adding a chemical tag called an acetyl group. By using molecules that glow fluorescently, the researchers saw under high-power microscopes that GCN5 carries its tagged target to a different location in the cell's nucleus – sequestering it away from the genes it's normally meant to turn on.

‘GCN5 has been generally shown to turn on genes. No one knew that GCN5 could be used to turn off pathways’ says Lerin. ‘It was a bit of a surprise.’

When the researchers put GCN5 into live mice, they found that it can in fact decrease blood glucose levels. Liver cells in mice that were given no food for 16 hours actively release glucose into the bloodstream. Introducing GCN5 into their livers, however, causes blood glucose levels in these mice to be reduced.

‘These results show that changing GCN5 is sufficient to control the sugar balance in mice,’ says Puigserver. ‘Therefore, GCN5 has the potential to be a target for therapeutic drug design in the future.’

Souce: Eurekalert
'"/>




Related medicine news :

1. Is Diabetes the Leading Cause of Kidney Failure in India
2. Diabetes and Depression often go hand-in-hand
3. Thirty minutes of work up per day reduces the risk of Diabetes
4. Diabetes on the rise
5. Irregular Periods Linked to Diabetes
6. Cinnamon combats Diabetes
7. Good News For Women With Gestational Diabetes
8. Processed Meat, Diabetes connection Found
9. Pancreatic Cancer may be linked to Diabetes
10. Gestational Diabetes linked to Chromosomal defici
11. A way to slow the progression of Type 1 Diabetes
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:6/25/2016)... ... June 25, 2016 , ... ... and applications at AcademyHealth’s Annual Research Meeting June 26-28, 2016, at the Hynes ... important health care topics including advance care planning, healthcare costs and patient and ...
(Date:6/25/2016)... ... , ... As a lifelong Southern Californian, Dr. Omkar Marathe earned his Bachelors ... Geffen School of Medicine at UCLA. He trained in Internal Medicine at Scripps Green ... hematology/oncology at the UCLA-Olive View-Cedars Sinai program where he had the opportunity to train ...
(Date:6/24/2016)... ... ... Those who have experienced traumatic events may suffer from a complex set of ... or alcohol abuse, as a coping mechanism. To avoid this pain and suffering, Serenity ... event. , Trauma sufferers tend to feel a range of emotions, from depression, guilt, ...
(Date:6/24/2016)... (PRWEB) , ... June 24, 2016 , ... ... now offering micro-osteoperforation for accelerated orthodontic treatment. Dr. Cheng has extensive experience with ... Damon brackets , AcceleDent, and accelerated osteogenic orthodontics. , Micro-osteoperforation is a ...
(Date:6/24/2016)... ... 24, 2016 , ... The Haute Beauty Network, affiliated with ... as a prominent plastic surgeon and the network’s newest partner. , Dr. ... handsome men, look naturally attractive. Plastic surgery should be invisible.” He stands by ...
Breaking Medicine News(10 mins):
(Date:6/26/2016)... -- One of Australia,s successful biotechnology scientists, ... new biotechnology company, Noxopharm Limited [ABN 50 608 966 123] ("Noxopharm"). ... list on the ASX. Noxopharm is a clinic-ready company ... Phase 1 clinical study later this year. ... biggest problems facing cancer patients - the ability of cancers to ...
(Date:6/26/2016)... 2016 Jazz Pharmaceuticals plc (Nasdaq: ... Hart-Scott-Rodino Antitrust Improvements Act of 1976, as amended ("HSR"), ... Inc. ("Celator"; Nasdaq: CPXX ) expired effective ... As previously announced on May 31, 2016, ... agreement under which Jazz Pharmaceuticals has commenced a tender ...
(Date:6/26/2016)... Ontario , June 27, 2016  VMS Rehab ... Company,s Board will take whatever measures required to build ... Company,s stock which is currently listed on the OTC ... Wexler, Company Chairman and CEO, "We are seeing an ... difficult to understand, not only by the Company, but ...
Breaking Medicine Technology: